These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11.
    Author: Sawyer TE, Bonner JA.
    Journal: Br J Cancer Suppl; 1996 Jul; 27():S109-13. PubMed ID: 8763860.
    Abstract:
    Buthionine sulphoximide (BSO)-induced depletion of glutathione (GSH) was found to be associated with an increased sensitivity to CPT-11 (topoisomerase I-reactive agent) in V79 hamster lung fibroblast cells. When V79 cells were exposed to 2.5 mM BSO for 28 h beginning 4 h prior to a 24 h coincubation with CPT-11, cytotoxicity was increased compared with CPT-11 alone. It was determined that BSO resulted in a G1 cell cycle arrest and a decrease in the percentage of cells in S-phase. Since CPT-11 is known to be S-phase-specific, this BSO-induced cell cycle redistribution did not appear to account for the chemosensitisation of CPT-11. Additionally, BSO did not alter intracellular accumulation of CPT-11, conversion of CPT-11 to its active metabolite SN-38, or efflux of either CPT-11 or SN-38 from the cell. Finally, BSO resulted in a slight reduction, rather than an increase, in the number of stabilised DNA-topoisomerase I complexes induced by CPT-11. Therefore, these results suggest that BSO-induced sensitisation of V79 cells to the cytotoxic effects of CPT-11 occurs by a mechanism independent of the stabilisation of DNA-topoisomerase I complexes.
    [Abstract] [Full Text] [Related] [New Search]